Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 407.56M P/E - EPS this Y 29.00% Ern Qtrly Grth -
Income -319.25M Forward P/E -2.23 EPS next Y 52.60% 50D Avg Chg 7.00%
Sales 54.9M PEG -0.01 EPS past 5Y - 200D Avg Chg -26.00%
Dividend N/A Price/Book 1.15 EPS next 5Y 45.80% 52W High Chg -55.00%
Recommedations 2.70 Quick Ratio 0.53 Shares Outstanding 193.91M 52W Low Chg 38.00%
Insider Own 0.44% ROA -36.24% Shares Float 193.13M Beta 0.80
Inst Own 43.40% ROE -186.70% Shares Shorted/Prior 48.40M/41.14M Price 3.83
Gross Margin -38.67% Profit Margin - Avg. Volume 4,213,451 Target Price 2.75
Oper. Margin -548.99% Earnings Date Nov 5 Volume 2,991,750 Change 2.68%
About bluebird bio, Inc.

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

bluebird bio, Inc. News
08:10 AM Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates
07:08 AM Bluebird: Q3 Earnings Snapshot
07:00 AM bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
11/06/24 bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call
11/05/24 bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
10/31/24 bluebird bio (BLUE): Promising Gene Editing Stock with FDA-Approved Therapies
10/11/24 Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy
10/10/24 Bluebird bio’s Skysona led to seven cases of blood cancer in gene therapy trials
10/04/24 bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/27/24 Bluebird: Q2 Earnings Snapshot
09/27/24 bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing
09/24/24 Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year
09/24/24 bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025
09/13/24 bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q
08/28/24 FDA will not meet ahead of bluebird bio’s sickle cell disease gene therapy PDUFA date
08/28/24 bluebird bio Announces September Investor Events
08/23/24 bluebird bio Announces Receipt of Expected Notices from Nasdaq
06:00 AM bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
08/12/24 bluebird bio Announces Second Quarter 2024 Results Call Date
BLUE Chatroom

User Image WalterPayton Posted - 59 minutes from now

$BLUE

User Image Ntlacrsp Posted - 57 minutes from now

$BLUE https://finance.yahoo.com/news/bluebird-bio-blue-reports-q3-131003247.html

User Image Ntlacrsp Posted - 48 minutes from now

$BLUE Doesn’t look like Walled Street was impressed with Blues Earnings today… $10M in revenue, extreme short runway, no product demand ?? I don’t believe blue will get the votes for a reverse split ?? I am praying for a hostile takeover but I am not sure there are any takers at this point?? It will be awhile before there is demand for LYFGENIA and blue sure doesn’t have the runway for waiting. Looks like others don’t see any value in blue … based on little revenue and no offers to buy?? But the beat goes on??

User Image Rosvit Posted - 7 minutes from now

$BLUE Its horrible..Price 0'36 USD IS JOKE?? FUCK CEO

User Image Gdoubleup Posted - 1 minute from now

$BLUE

User Image gargoyl Posted - 1 hour ago

$BLRX $BLUE watching MM on LTSE exchange playing both sides book

User Image Gdoubleup Posted - 1 hour ago

$BLUE test support .3648 IMO

User Image BioTechChap Posted - 1 hour ago

$BLUE No presentation with today's ER call? Can't find on IR page.

User Image Stockgang1 Posted - 1 hour ago

$BLUE let’s goo! Any time now

User Image blueb22 Posted - 1 hour ago

$BLUE - listened to ER call recording. All good and reassuring to me. Retail Investors: please don't play into the hands of fear mongering happening here. Yes, there few real investors and since long time and suffering a lot (like me too) with high average and this price dropping regardless of any new (even some good news) and are frustrated (I too am frustrated) and RS usually results in bad outcome for investors, but I beleive it will not be the case here as there is huge tailwind coming here in next few weeks and months to propel price higher. But then there are many posters here who are not real investors and not even retail shorts, they are paid bashers working for 'someone' (or more than one) to suppress and manipulate price here. I still believe in BLUE and we are getting closer to better days ahead. (I will post many of my views over the weeknd) Good Luck real investors. Fingers crossed 🤞

User Image Noahman Posted - 1 hour ago

$BLUE, sure. I truly believe their message.

User Image Gdoubleup Posted - 2 hours ago

$BLUE

User Image Dkll303 Posted - 2 hours ago

$ADAP Yes this has been a POS for over 2 years , just like $BLUE

User Image Pianomemo Posted - 2 hours ago

$BLUE so basically they secured the financing until Cashflow even in 2025 and expect a revenue surge in next year. 27% guess they gonna cover now same as $ASTS $EBS $MARA

User Image Tommystar2121 Posted - 2 hours ago

$BLUE only a matter of time a big biotech will gobble this company. PT $8

User Image Tommystar2121 Posted - 2 hours ago

$BLUE Top buy out target.. 🎯

User Image Stockgang1 Posted - 2 hours ago

$BLUE get on it while you can

User Image Espre Posted - 2 hours ago

$BLUE From the Q3 call - Blue management. There's currently 35M shares available to be issued, this will be maintained/fixed in a potential R/S. With a R/S of 20 to 1 or 15 to 1, that's like giving 20 to 15x of the value of your shares away. Looking for an argument that could justify that strategy, I'm turning more skeptical with every quarterly meeting. I see how it's a great way to reaquire control/ownership from current investors. Any argument as a current investor why it would be good to hold through that process?

User Image Bio2015 Posted - 3 hours ago

$BLUE Worse case scenario would be bankruptcy. If so, then asset sale would be a boost to $BLUE SP. $VRTX CEO stated Casgevy a ’multi-billion dollar opportunity’. If so, and Lyfgenia/Zynteglo sales exceeds Casgevy, then Lyf/Zyn asset sale should easily be worth $1B+ to $BLUE investors.

User Image Stockgang1 Posted - 3 hours ago

$BLUE here you go: bluebird bio’s commercial progress, including the strong demand for its gene therapies and the company’s ongoing efforts to expand access through reimbursement strategies. The presentation of updated clinical trial data at ASH 2024 highlights the continued development of its therapies for sickle cell disease and beta-thalassemia, and the stocks to have positive sentiment and growth!

User Image mikeg1999 Posted - 3 hours ago

@Bio2015 you have two quarters worth of data and are trying to extrapolate that long term. the difference is that Casgevy ATCs are still ramping up while $BLUE already has all of its established sites. you also forget that Lyfgenia is only approved in the US whereas Casgevy is internationally approved. these just can’t be compared right now.

User Image Bio2015 Posted - 3 hours ago

Sub-$100M $BLUE is beating $125B Goliath $VRTX $CRSP in SCD/TDT by patient starts. Amazing given disparity in financial resources. Despite unwarranted black box warning (no cancer cases from Lyfgenia with updated vector), physicians are choosing Lyfgenia/Zynteglo over Casgevy. From latest ER’s: Lyfgenia/Zynteglo with 52 patient starts YTD (excluding Skysona); Casgevy with 40. Q/Q Lyf/Zyn increased from 23 patients in 2nd Q to 29 patients in 3rd Q. Lyf/Zyn starts are accelerating. Casgevy patient starts flat Q/Q with 20 in each Q. This is huge long-term with Lyf/Zyn sales accelerating while Cas sales remaining flat. Long-term, as long as $BLUE Lyf/Zyn sales accelerating, $BLUE will survive/eventually thrive. If Lyf/Zyn sales were lagging Casgevy, then $BLUE investors should worry a lot. $BLUE just needs to get over short-term financing hump. By end of 2025, $BLUE should be a multi-bagger. Takes guts to hang onto a stock that is tanking everyday.

User Image Pianomemo Posted - 3 hours ago

$BLUE Imagine being a short here to short this to Oblivion. What if it turns and the ramp up just started? Take your bag and move along

User Image look2theblue Posted - 3 hours ago

$BLUE My sense is that the individuals short 47 million shares are a disappointed with today's earnings call. They were counting on bad news, but instead they got continued growth and new patient starts. Not good for their fake doom and gloom narrative.

User Image Humperdink Posted - 3 hours ago

$BLUE Reverse split approval will see Mass covering of short shares. Once the reverse split is enacted, we will have something called a super low float around 9 or 10 million. Shorts know if they try to cover with a low float it will push the share price into the stratosphere. Now imagine, andrew obenshain enacts a reverse split, then announces a partnership or other good news. The share price can go from $5 area to $40.00 or $50 in a split second kind of like it did with DRUG. Now Andrew does a smallish offering around $50.00 for a few hundred million bucks without adding massive dilution. Andrew wants a reverse split to benefit us. VOTE YES TO REVERSE SPLIT

User Image blueb22 Posted - 3 hours ago

$BLUE - I agree. I wish their is good buyer and management agree to come to negotiation table and sale for $4-5 range, but it is hard in current situation where due to SP and this cash raise/dilution fear etc, they are able press BLUE and corner them to sale for even $2 and that is what they are doing now and very desperately here as once CMS OBA signed at end of Nov (hopefully CMS is on target with that timeline) and now we are seeing rev realization of $25m in Q4, $45-48m in Q1, $70m in Q2, and possibly $90m in Q3 (assuming 40 starts in Q1) and so on, this SP will fly higher once funding issue is resolved. BLUE need RS and may be some dilutive cash and atleast that tool to survive and fight this constant attacks.

User Image Humperdink Posted - 3 hours ago

$BLUE pretty sure I heard 30 patients booked q1. That's 90 million revenue and we still have another half a quarter to book another 30 patients for q1. If we book 60 patients for q1 the share price here can head parabolic and easily gap fill that $2.40. That's nearly 200 million revs for q1

User Image Coolrunnniz Posted - 3 hours ago

$BLUE Not voting in favor a r/s regardless of what the mentally unstable guy below me says. if break even is that close renegotiate with hercules.

User Image Humperdink Posted - 3 hours ago

$BLUE double bounce off 52 week low means the likelihood of a significant recovery is just starting here. With near 50 million shares short and revenue headed parabolic, expect a steady rise in share price. Revenue ramp has begun and will not reverse. Share price should start to reflect in the coming weeks. If Andrew can use the reverse split to our advantage, he will save good news until after reverse split and a super low float of 10 million shares. Price with short covering can head parabolic. This is no time to sit and watch as we will be headed much higher sooner than later. Pay attention and VOTE YES TO REVERSE SPLIT!!!

User Image stock_master84 Posted - 3 hours ago

$BLUE All - u guys have no idea. Blue is done, there is ntg left. RS vote will go through, I mean they will find a way. They will do 20:1, the stock price will settle around $6 after RS, and OS at 10M, then they will raise $100M at $4-$5, that will be dilution 2-3 times of OS, so it will be a massive dilution. Chances that the share price will get to $2 are high… After it settles in $2 range we are back where we were earlier this year. So the real question is do you stick around knowing RS and dilution this year is inevitable and you will loose another 50% from current level. And do you trust this management team to deliver this time? If the answer is No to either one, you sell and move on, if Yes to both u invest and pray hard. FYI - there is less than 1% chance they will get partner or BO, so that is off the table.

Analyst Ratings
Wells Fargo Equal-Weight Sep 25, 24
Cantor Fitzgerald Neutral Sep 16, 24
B of A Securities Buy Aug 15, 24
RBC Capital Sector Perform Aug 15, 24
Barclays Overweight Aug 15, 24
Baird Outperform Aug 15, 24
JP Morgan Neutral Aug 15, 24
RBC Capital Sector Perform Mar 27, 24
Wells Fargo Equal-Weight Mar 27, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Klima Thomas J See Remarks See Remarks Feb 05 Sell 0.9025 2,714 2,449 129,413 02/06/24
Vittiglio Joseph Chief Business & Leg.. Chief Business & Legal Officer Feb 05 Sell 0.9025 5,217 4,708 44,783 02/06/24
Obenshain Andrew President and CEO President and CEO Feb 05 Sell 0.9025 1,879 1,696 286,093 02/06/24
Obenshain Andrew President and CEO President and CEO Aug 10 Sell 3.5416 16,929 59,956 291,941 08/10/23
Obenshain Andrew President and CEO President and CEO Jan 11 Sell 7.8043 3,178 24,802 242,690 01/13/23
Colvin Richard A Chief Medical Office.. Chief Medical Officer Jan 11 Sell 7.8043 557 4,347 74,231 01/13/23
Leschly Nick Director Director Jan 11 Sell 7.8043 4,290 33,480 280,149 01/13/23
Colvin Richard A Chief Medical Office.. Chief Medical Officer Nov 04 Sell 6.4137 218 1,398 74,788 11/08/22
Obenshain Andrew President and CEO President and CEO Nov 04 Sell 6.4137 1,263 8,101 245,868 11/08/22
Cole Jason Chief Strategy & Fin.. Chief Strategy & Financial Off Aug 19 Sell 5.5286 14,194 78,473 189,546 08/23/22
Whitten Jessica Chief Accounting Off.. Chief Accounting Officer Jan 10 Sell 9.52 409 3,894 49,413 01/12/22
Cole Jason Chief Operating and Chief Operating and Jan 10 Sell 9.52 4,971 47,324 186,188 01/12/22
Leschly Nick Director Director Jan 10 Sell 9.52 7,437 70,800 281,330 01/12/22
Obenshain Andrew President and CEO President and CEO Jan 10 Sell 9.43 7,725 72,847 246,696 01/12/22
Leschly Nick President and CEO President and CEO Jan 08 Sell 45.06 10,428 469,886 87,263 01/08/21
Baird William D III Chief Financial Offi.. Chief Financial Officer Jan 08 Sell 45.11 949 42,809 22,797 01/08/21
FINGER ALISON CECILY Chief Commercial Off.. Chief Commercial Officer Jan 08 Sell 45.06 1,854 83,541 25,103 01/08/21
Davidson David Chief Medical Office.. Chief Medical Officer Jan 08 Sell 45.06 3,215 144,868 36,361 01/08/21
Cole Jason Chief Operating and Chief Operating and Jan 08 Sell 45.06 2,401 108,189 32,823 01/08/21
Smith-Farrell Joanne COO, Oncology COO, Oncology Jan 08 Sell 45.06 1,329 59,885 20,609 01/08/21
Gregory Philip D Chief Scientific Off.. Chief Scientific Officer Jan 08 Sell 45.06 2,799 126,123 33,007 01/08/21
FINGER ALISON CECILY Chief Commercial Off.. Chief Commercial Officer Dec 04 Sell 46.34 36 1,668 26,957 12/04/20
Smith-Farrell Joanne COO, Oncology COO, Oncology Dec 04 Sell 46.34 38 1,761 21,938 12/04/20
Cole Jason Chief Operating and Chief Operating and Dec 04 Sell 46.34 38 1,761 35,224 12/04/20
Gregory Philip D Chief Scientific Off.. Chief Scientific Officer Dec 04 Sell 46.34 59 2,734 35,806 12/04/20
Davidson David Chief Medical Office.. Chief Medical Officer Dec 04 Sell 46.34 64 2,966 39,576 12/04/20